Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences (NYSE:RCUS), a clinical-stage global biopharmaceutical company focusing on cancer treatments, has announced new employment inducement grants. The Compensation Committee of the company's Board of Directors has granted four new employees options to purchase a total of 24,100 shares of common stock at an exercise price of $17.47 per share, which was the closing price on October 8, 2024. Additionally, these employees received restricted stock units to acquire a total of 12,050 shares of common stock.

These equity awards were granted under the company's 2020 Inducement Plan, which was approved by the Board of Directors in January 2020 in accordance with the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences (NYSE:RCUS) will present first clinical data from the ARC-20 study at the 2024 EORTC-NCI-AACR Symposium. The oral presentation will highlight data from the 100mg daily monotherapy expansion cohort of ARC-20, a Phase 1/1b study evaluating casdatifan in late-line clear cell renal cell carcinoma (ccRCC). Data will include safety, efficacy, objective response rate, and rate of primary progression.

Arcus is pursuing a broad development program for casdatifan in ccRCC, including the planned initiation of their first Phase 3 study, PEAK-1, in the first half of 2025. The company will also present posters on casdatifan's preclinical evaluation, human pharmacokinetics/pharmacodynamics, and AB801, Arcus's AXL inhibitor.

A conference call to discuss the ARC-20 results will be held on October 24, 2024, at 5:00 AM PT / 8:00 AM ET.

Arcus Biosciences (NYSE:RCUS) has announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan (AB521), Arcus's investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, in patients with clear cell renal cell carcinoma (ccRCC). This marks the second clinical collaboration between the two companies.

The study, sponsored and operationalized by AstraZeneca, aims to assess the safety and early efficacy of the combination therapy in advanced ccRCC patients. Arcus believes casdatifan has best-in-class potential based on observed PK and PD profiles and emerging clinical data from their ARC-20 study. The collaboration seeks to improve outcomes for ccRCC patients by combining HIF-2a inhibition with volrustomig.

Under the Gilead and Arcus collaboration agreement, Gilead retains the right to opt-in to development and commercialization for casdatifan after Arcus delivers a qualifying data package.

Arcus Biosciences (NYSE:RCUS), a clinical-stage global biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer, has announced new employment inducement grants. The Compensation Committee of the Company's Board of Directors has granted five new employees options to purchase 38,600 shares of the Company's common stock at an exercise price of $15.71 per share, which was the closing price on September 23, 2024. Additionally, restricted stock units to acquire 19,300 shares of the Company's common stock were granted. These equity awards were granted under the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced new employment inducement grants. The Compensation Committee of the company's Board of Directors has awarded four new employees with:

• Options to purchase a total of 27,800 shares of common stock at an exercise price of $16.31 per share
• Restricted stock units to acquire a total of 13,900 shares of common stock

These equity awards were granted under Arcus Biosciences' 2020 Inducement Plan, approved by the Board in January 2020 under the NYSE Listed Company Manual Rule 303A.08 'inducement exception'.

Arcus Biosciences (NYSE:RCUS) has secured a $250 million term loan facility from Hercules Capital, enhancing its financial position and operational flexibility. The facility includes $150 million committed, with $50 million drawn at closing and $100 million available at Arcus's discretion. This non-dilutive funding will support the recently announced Phase 3 PEAK-1 study for casdatifan, Arcus's HIF-2a inhibitor for clear cell renal cell carcinoma (ccRCC). The loan matures in five years, extendable to six, with an interest-only period of four years, extendable to five based on regulatory milestones. This financial boost allows Arcus to accelerate its development program for casdatifan across multiple ccRCC settings.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focusing on cancer therapies, has announced new employment inducement grants. The Compensation Committee of the company's Board of Directors has granted three new employees options to purchase 21,100 shares of common stock at an exercise price of $18.01 per share, which was the closing price on August 23, 2024. Additionally, restricted stock units to acquire 10,550 shares of common stock were granted. These equity awards were issued under the company's 2020 Inducement Plan, approved by the Board in January 2020 under the 'inducement exception' of NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced its participation in two upcoming investor conferences in September 2024:

• The Morgan Stanley 22nd Annual Global Healthcare Conference on September 4th at 4:55 p.m. ET in New York, NY
• The Cantor Fitzgerald Global Healthcare Conference 2024 on September 19th at 10:55 a.m. ET in New York, NY

Both events will feature fireside chats with Arcus Biosciences' management team. Live webcasts of these sessions will be available on the company's website under the 'Investors & Media' section, with replays accessible after the events.

Arcus Biosciences (NYSE:RCUS) released its Q2 2024 financial results and provided updates on its clinical pipeline. The company reported $39 million in revenue, up from $29 million YoY, and a net loss of $93 million, compared to $75 million last year. R&D expenses rose to $115 million due to late-stage programs. Arcus maintains a cash runway into 2027 with $1 billion in cash and equivalents.

Pipeline highlights include casdatifan data presentations at a medical conference in Q4 2024 and a Phase 3 study (PEAK-1) set to begin in H1 2025. The Phase 3 STAR-221 study for domvanalimab + zimberelimab with chemotherapy in upper GI cancers has completed enrollment. Additionally, the PRISM-1 Phase 3 study for quemliclustat in pancreatic cancer will start by early 2025.

Notably, Taiho Pharmaceutical has exercised its option on quemliclustat for Japan and certain Asian territories, leading to potential milestone payments to Arcus. Overall, Arcus continues to advance its pipeline with significant updates anticipated over the next 18 months.